Potential Cardiometabolic Benefits of Renal Artery Denervation in DiabeticsSuraj Maraj1, Rikesh Patel1, Rene Oliveros2*, Saurabh Sanon1, Tim Dao1, Sik Hur1 and Robert Chilton1,2
- *Corresponding Author:
- Oliveros Rene
Division of Cardiology
The University of Texas Health Science Center at
San Antonio and Janey Briscoe Center of Excellence for CV Research
San Antonio, USA
E-mail: [email protected]
Received date May 23, 2011; Accepted date July 06, 2012; Published date July 11, 2012
Citation: Maraj S, Patel R, Oliveros R, Sanon S, Dao T, et al. (2012) Potential Cardiometabolic Benefits of Renal Artery Denervation in Diabetics. J Diabetes Metab S3:007. doi:10.4172/2155-6156.S3-007
Copyright: © 2012 Maraj S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Treatment of hypertension using renal artery sympathetic denervation was first reported as early as 1924, but only recently has the advent of safer, less invasive techniques allowed this treatment modality to emerge as a promising treatment for hypertension. Aside from reductions in blood pressure, the effect of this treatment appears to be more widespread than initially thought. Renal artery sympathetic denervation may globally reduce cardiovascular risk through a variety of mechanisms such as decreased insulin resistance, oxidative stress, and organ hypertrophy, along with improvement in diastolic function and other metabolic parameters. The following is a comprehensive review of current literature on renal artery sympathetic denervation with a focus on potential cardiovascular benefits.